Finasteride works by specifically targeting and blocking the type II 5α-reductase enzyme. This enzyme plays a crucial role in converting testosterone into dihydrotestosterone (DHT). By inhibiting this conversion, finasteride significantly reduces the amount of DHT produced in the body.
Understanding the Enzyme’s Role
The 5α-reductase enzyme exists in two isoforms: type I and type II. Type II is predominantly found in the prostate, scalp, and other androgen-sensitive tissues. Finasteride selectively inhibits type II, resulting in a more targeted reduction of DHT without broadly impacting other steroid hormones. This selective inhibition is key to its effectiveness in treating conditions like male pattern baldness and benign prostatic hyperplasia (BPH).
The reduction in DHT levels achieved through finasteride use varies depending on dosage and individual factors, but studies consistently demonstrate a substantial decrease. This decrease directly translates to a slowdown or reversal of DHT-driven processes, like hair follicle miniaturization in androgenetic alopecia or prostate growth in BPH.
